AACR IO 2026 Keynote Highlights: Cancer Vaccines Are Here, and Upgrading T Cells To Thrive in the Tumor Microenvironment
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the...
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the...
At the end of last week, the U.S. Food and Drug Administration (FDA) announced the approval of the first...
Members of the AACR Project GENIE consortium presented their first analyses of the data during the Pan-Cancer Genomic Analysis...
May is National Cancer Research Month, during which the American Association for Cancer Research partners with advocacy groups, cancer...
On Thursday, the U.S. Food and Drug Administration (FDA) expanded the use of the antiangiogenic therapeutic regorafenib (Stivarga) to...
The U.S. Preventive Services Task Force (USPSTF) released draft recommendations April 11 suggesting that doctors inform men ages 55...
The American Association for Cancer Research (AACR) Annual Meeting 2017 brought some of the world’s greatest scientific minds to...
Last month, U.S. Rep. Donald Payne Jr. (D-New Jersey), led a roundtable discussion at University Hospital in Newark, New...
Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate...
On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with...
Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers...